DANYELZA commercialization is progressing throughout the U.S.

DANYELZA BLA submission accepted by the National Medical Products Administration of China.

Submitted the European Marketing Authorization Application to the European Medicines Agency for omburtamab in April.

Awaiting positive Type B meeting with the FDA in the third quarter to initiate rolling resubmission of the omburtamab BLA by the end of the year.